Thompson Siegel & Walmsley’s Medtronic MDT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $10.9M | Buy |
139,007
+32,513
| +31% | +$2.62M | 0.2% | 131 |
|
|
2026
Q1 | $9.23M | Hold |
106,494
| – | – | 0.16% | 136 |
|
|
2025
Q4 | $10.2M | Hold |
106,494
| – | – | 0.17% | 129 |
|
|
2025
Q3 | $10.1M | Buy |
106,494
+43,000
| +68% | +$3.95M | 0.16% | 135 |
|
|
2025
Q2 | $5.54M | Buy |
63,494
+30,017
| +90% | +$2.55M | 0.09% | 202 |
|
|
2025
Q1 | $3.01M | Buy |
+33,477
| New | +$3M | 0.05% | 224 |
|
|
2024
Q1 | – | Sell |
-33
| Closed | -$3K | – | 461 |
|
|
2023
Q4 | $3K | Sell |
33
-20
| -38% | -$1.52K | ﹤0.01% | 506 |
|
|
2023
Q3 | $4K | Sell |
53
-1,870
| -97% | -$157K | ﹤0.01% | 507 |
|
|
2023
Q2 | $169K | Hold |
1,923
| – | – | ﹤0.01% | 364 |
|
|
2023
Q1 | $155K | Sell |
1,923
-990
| -34% | -$80.7K | ﹤0.01% | 372 |
|
|
2022
Q4 | $226K | Sell |
2,913
-277
| -9% | -$22.5K | ﹤0.01% | 334 |
|
|
2022
Q3 | $258K | Hold |
3,190
| – | – | ﹤0.01% | 326 |
|
|
2022
Q2 | $286K | Sell |
3,190
-324
| -9% | -$32.8K | ﹤0.01% | 317 |
|
|
2022
Q1 | $390K | Hold |
3,514
| – | – | 0.01% | 329 |
|
|
2021
Q4 | $364K | Hold |
3,514
| – | – | 0.01% | 332 |
|
|
2021
Q3 | $440K | Buy |
3,514
+2,913
| +485% | +$377K | 0.01% | 315 |
|
|
2021
Q2 | $75K | Sell |
601
-256
| -30% | -$32.1K | ﹤0.01% | 456 |
|
|
2021
Q1 | $101K | Sell |
857
-433
| -34% | -$50.7K | ﹤0.01% | 405 |
|
|
2020
Q4 | $151K | Sell |
1,290
-25
| -2% | -$2.75K | ﹤0.01% | 351 |
|
|
2020
Q3 | $137K | Hold |
1,315
| – | – | ﹤0.01% | 347 |
|
|
2020
Q2 | $121K | Sell |
1,315
-200
| -13% | -$19.2K | ﹤0.01% | 356 |
|
|
2020
Q1 | $137K | Sell |
1,515
-579
| -28% | -$61.6K | ﹤0.01% | 338 |
|
|
2019
Q4 | $238K | Buy |
2,094
+430
| +26% | +$47.2K | ﹤0.01% | 368 |
|
|
2019
Q3 | $181K | Buy |
1,664
+67
| +4% | +$6.99K | ﹤0.01% | 394 |
|
|
2019
Q2 | $156K | Sell |
1,597
-31,360
| -95% | -$2.86M | ﹤0.01% | 407 |
|
|
2019
Q1 | $3M | Buy |
32,957
+5,515
| +20% | +$494K | 0.04% | 183 |
|
|
2018
Q4 | $2.5M | Buy |
27,442
+26,400
| +2,534% | +$2.47M | 0.04% | 188 |
|
|
2018
Q3 | $103K | Sell |
1,042
-220
| -17% | -$20.3K | ﹤0.01% | 452 |
|
|
2018
Q2 | $108K | Sell |
1,262
-500
| -28% | -$41.8K | ﹤0.01% | 458 |
|
|
2018
Q1 | $141K | Sell |
1,762
-200
| -10% | -$16.5K | ﹤0.01% | 428 |
|
|
2017
Q4 | $158K | Sell |
1,962
-100
| -5% | -$8.01K | ﹤0.01% | 437 |
|
|
2017
Q3 | $160K | Sell |
2,062
-365
| -15% | -$30.3K | ﹤0.01% | 427 |
|
|
2017
Q2 | $215K | Sell |
2,427
-835
| -26% | -$70.4K | ﹤0.01% | 422 |
|
|
2017
Q1 | $263K | Sell |
3,262
-89,998
| -97% | -$7.03M | ﹤0.01% | 437 |
|
|
2016
Q4 | $6.64M | Sell |
93,260
-12,242
| -12% | -$962K | 0.09% | 215 |
|
|
2016
Q3 | $9.12M | Sell |
105,502
-17,855
| -14% | -$1.56M | 0.14% | 200 |
|
|
2016
Q2 | $10.7M | Sell |
123,357
-18,325
| -13% | -$1.48M | 0.17% | 178 |
|
|
2016
Q1 | $10.6M | Sell |
141,682
-11,016
| -7% | -$830K | 0.17% | 182 |
|
|
2015
Q4 | $11.7M | Buy |
152,698
+7,073
| +5% | +$532K | 0.21% | 169 |
|
|
2015
Q3 | $9.75M | Sell |
145,625
-27,615
| -16% | -$2.03M | 0.18% | 191 |
|
|
2015
Q2 | $12.8M | Buy |
173,240
+560
| +0.3% | +$42.8K | 0.23% | 178 |
|
|
2015
Q1 | $13.5M | Sell |
172,680
-2,025
| -1% | -$153K | 0.23% | 173 |
|
|
2014
Q4 | $12.6M | Buy |
174,705
+3,605
| +2% | +$250K | 0.24% | 164 |
|
|
2014
Q3 | $10.6M | Buy |
171,100
+113,590
| +198% | +$7.22M | 0.21% | 181 |
|
|
2014
Q2 | $3.67M | Buy |
+57,510
| New | +$3.49M | 0.07% | 239 |
|
Other funds holding MDT
Thompson Siegel & Walmsley's MDT Position: Q2 2026 in Review
Thompson Siegel & Walmsley increased its Medtronic (MDT) stake by 31% in Q2 2026, buying an estimated $2.62M and bringing the position to 139,007 shares worth $10.9M. The position accounts for 0.2% of the portfolio, ranked #131.
Thompson Siegel & Walmsley first reported a position in MDT in Q2 2014 and has held it in 45 quarters since. The position peaked at $13.5M in Q1 2015. 2,128 funds tracked by Wall St. Rank hold MDT as of Q2 2026.
- Thompson Siegel & Walmsley held 139,007 shares of Medtronic worth $10.9M as of Q2 2026.
- Thompson Siegel & Walmsley bought 32,513 Medtronic shares in Q2 2026, an estimated $2.62M.
- Medtronic made up 0.2% of Thompson Siegel & Walmsley's portfolio in Q2 2026, its #131 holding.
- Thompson Siegel & Walmsley first reported a position in Medtronic in Q2 2014 and has held it in 45 quarters since.
- Thompson Siegel & Walmsley's Medtronic position peaked at $13.5M in Q1 2015.
- 2,128 funds tracked by Wall St. Rank held Medtronic as of Q2 2026.
Based on Thompson Siegel & Walmsley's 13F filing for Q2 2026, filed 11 Aug 2026.